Nečistoće aminokiseline koja se koriste za sintetizirati protein
Detalj proizvoda
| NO | Proizvodi | CAS br | Indikator ključeva | |||
| Čistoća | Maks. nečistoća | Ukupni ostaci otapala | Vlaga | |||
| 1 | Fmoc-β-ala-ala-oh | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 2 | FMOC-D-ALA-D-ALA-OH | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 3 | FMOC-β-ala-D-ala-oh | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 4 | FMOC-ARG (PBF) -ARG (PBF) -OH | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 5 | FMOC-β-ala-arg (PBF) -OH | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 6 | FMOC-D-ARG (PBF) -D-ARG (PBF) -OH | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 7 | FMOC-β-ALA-D-ARG (PBF) -OH | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 8 | FMOC-Homoarg (PBF) -Homoarg (PBF) -OH | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 9 | FMOC-β-Ala-Homoarg (PBF) -OH | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 10 | FMOC-ASN (TRT) -ASN (TRT) -OH | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 11 | Fmoc-β-ala-ASN (TRT) -OH | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 12 | FMOC-ASP (otbu) -asp (otbu) -Oh | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 13 | FMOC-β-ALA-ASP (otbu) -Oh | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 14 | FMOC-CYS (TRT) -cys (TRT) -Oh | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 15 | FMOC-β-Ala-CYS (TRT) -OH | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 16 | FMOC-CYS (ACM) -cys (ACM) -OH | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 17 | FMOC-β-Ala-Cys (ACM) -OH | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 18 | FMOC-GLN (TRT) -GLN (TRT) -OH | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 19 | Fmoc-β-ala-GLN (TRT) -OH | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 20 | FMOC-GLU (otbu) -glu (otbu) -Oh | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 21 | Fmoc-β-ala-glu (otbu) -Oh.h2o | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 22 | Fmoc-β-ala-gly-oh | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 23 | FMOC-HIS (TRT) -HIS (TRT) -OH | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 24 | Fmoc-β-ala-njegov (trt) -oh | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 25 | Fmoc-ile-ile-oh | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 26 | FMOC-β-ala-ile-oh | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 27 | Fmoc-leu-leu-oh | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 28 | Fmoc-β-ala-leu-oh | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 29 | FMOC-D-Leu-D-leu-oh | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 30 | Fmoc-β-ala-D-leu-oh | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 31 | FMOC-Lys (BOC) -Le (boc) -Oh | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 32 | FMOC-β-ala-Lys (Boc) -Oh | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 33 | FMOC-Lys (ALLOC) -Le (ALLOC) -OH | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 34 | FMOC-β-ala-Lys (ALLOC) -OH | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 35 | Fmoc-met-met-oh | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 36 | Fmoc-β-ala-met-oh | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 37 | FMOC-ORN (boc) -orn (boc) -Oh | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 38 | FMOC-β-ala-ORN (BOC) -OH | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 39 | Fmoc-fe-fe-oh | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 40 | FMOC-β-ala-fe-oh | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 41 | FMOC-D-FE-D-FHE-OH | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 42 | Fmoc-β-ala-d-fe-oh | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 43 | Fmoc-pro-pro-oh | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 44 | Fmoc-β-ala-pro-oh | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 45 | FMOC-SER (TBU) -Ser (TBU) -OH | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 46 | Fmoc-β-ala-ser (TBU) -OH | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 47 | FMOC-SER (TRT) -Ser (TRT) -OH | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 48 | Fmoc-β-ala-ser (TRT) -OH | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 49 | FMOC-THR (TBU) -H45 (TBU) -OH | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 50 | FMOC-β-ALA-TH (TBU) -OH | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 51 | FMOC-TRP (BOC) -TRP (BOC) -OH | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 52 | FMOC-β-ALA-TRP (BOC) -OH | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 53 | FMOC-D-TRP (BOC) -D-TRP (BOC) -OH | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 54 | FMOC-β-ALA-D-TRP (BOC) -OH | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 55 | Fmoc-Tyr (TBU) -Tyr (TBU) -Oh | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 56 | Fmoc-β-ala-Tyr (TBU) -OH | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 57 | FMOC-D-Tyr (ET) -D-Tyr (ET) -OH | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 58 | FMOC-β-ala-D-Tyr (ET) -OH | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 59 | Fmoc-tyr (ja) -Tyr (ja) -Oh | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 60 | Fmoc-β-ala-Tyr (ja) -Oh | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 61 | Fmoc-val-val-oh | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 62 | FMOC-β-ala-val-oh | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 63 | FMOC-D-CIT-D-CIT-OH | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 64 | FMOC-β-ALA-D-CIT-OH | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 65 | Fmoc-β-ala-dab-oh | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 66 | FMOC- (3- (2-nafthil) -D-ala) 2-oh | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 67 | FMOC-β-ala-3- (2-naftil) -D-ala-oh | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 68 | FMOC- (3- (3-piridinil) -D-ala) 2-oh | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 69 | FMOC-β-ala-3- (3-piridinil) -D-ala-oh | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 70 | FMOC- (4-kloro-d-fe) 2-oh | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 71 | FMOC-β-ala-4-hloro-d-fe-oh | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 72 | FMOC- (D-4AFH (TBUCBM)) 2-Oh | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 73 | FMOC-β-Ala-D-4aph (TBUCBM) -OH | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 74 | FMOC-APH (L-HOR) -Aph (l-hor) -Oh | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 75 | FMOC-β-Ala-APH (L-HOR) -OH | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 76 | FMOC-Lys (IPR, BOC) -Le (IPR, BOC) -OH | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 77 | FMOC-β-ala-Lys (IPR, boc) -OH | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 78 | Fmoc-β-ala-aeea-oh | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 79 | FMOC-AIB-AIB-OH | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 80 | FMOC-β-ala-AIB-OH | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 81 | Fmoc-ass-oh | 91000-69-0 | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 82 | H-ARG (PBF) -OH | 200115-86-2 | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 83 | FMOC-D-ARG-OH | 130752-32-8 | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 84 | HD-ARG (PBF) -OH | 200116-81-0 | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 85 | Fmoc-homoarg-oh.hcl | 208174-14-5 | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 86 | H-Homoarg (PBF) -OH | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 87 | Fmoc-d-homoarg-oh | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 88 | HD-Homoarg (PBF) -OH | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 89 | Fmoc-asn-oh | 71989-16-7 | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 90 | H-ASN (TRT) -OH | 132388-58-0 | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 91 | Fmoc-asp-oh | 119062-05-4 | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 92 | H-ASP (otbu) -Oh | 3057-74-7 | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 93 | Fmoc-cys-oh | 135248-89-4 | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 94 | H-CYS (TRT) -OH | 2799/7/7 | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 95 | H-CYS (ACM) -OH.HCL | 28798-28-9 | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 96 | Fmoc-glen-oh | 71989-20-3 | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 97 | H-GLN (TRT) -OH | 102747-84-2 | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 98 | Fmoc-glu-oh | 121343-82-6 | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 99 | H-glu (otbu) -Oh.h2o | 2419-56-9 | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 100 | Fmoc-hit-oh | 116611-64-4 | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 101 | H -TY (TRT) -OH | 35146-32-8 | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 102 | Boc-njegov-oh | 17791-52-5 | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 103 | Fmoc-lys-oh | 105047-45-8 | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 104 | H-Lys (Boc) -Oh | 2418-95-3 | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 105 | H-Lys (ALLOC) -Oh | 6298/3/9 | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 106 | Fmoc-orn-oh.hcl | 201046-57-3 | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 107 | H-ORN (BOC) -OH | 13650-49-2 | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 108 | Fmoc-ser-oh | 73724-45-5 | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 109 | H-SER (TBU) -OH | 18822-58-7 | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 110 | H-SER (TRT) -OH | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 111 | FMOC-TP-OH.H2O | 73731-37-0 | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 112 | H-THR (TBU) -Oh | 4378-13-6 | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 113 | FMOC-TRP-OH | 35737-15-6 | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 114 | H-TRP (BOC) -OH | 146645-63-8 | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 115 | FMOC-D-TRP-OH | 86123-11-7 | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 116 | HD-TRP (BOC) -OH | 201290-11-1 | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 117 | Fmoc-tyr-oh | 92954-90-0 | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 118 | H-Tyr (TBU) -Oh | 18822-59-8 | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 119 | Fmoc-d-tyr-oh | 112883-29-1 | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 120 | HD-Tyr (ET) -Oh | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 121 | H-Tyr (mene) -Oh.hcl | 67423-44-3 | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 122 | FMOC-D-4APH (CBM) -OH | 324017-22-3 | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 123 | HD-4aph (tbucbm) -Oh | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 124 | FMOC-Lys (IPR) -Oh | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
| 125 | H-Lys (IPR, boc) -Oh | NA | ≥98,0% | ≤1.0% | ≤8,0% | ≤2,0% |
O
Naknada
Gentolex pružaju vrhunske proizvode, ako bilo koji kvalitet proizvoda odgaja Klijent u traženom vremenskom okviru s dovoljnim dokazima, pružit ćemo potrebnu analizu i evaluaciju za pokretanje postupaka naknada.
Produkcija
Kapaciteti farmaceutskih proizvoda dostigli su gradu tona, kapaciteti hemijskih proizvoda dosežu 100tons + ocjenu, sposobnosti su dobro opremljene za posluživanje klijenata širom svijeta.
Istraživanje i razvoj
Svake godine postoji plan koji je uspostavio tim za istraživanje i razvoj koji će razviti različite nove proizvode, kada će se postavljati ciljevi, svaki član u timu morat će se nastaviti sa odgovornošću KPI-ja i sa poticajnom politikom.
